Myriad Genetics, Inc.

NasdaqGS:MYGN Stock Report

Market Cap: US$1.4b

Myriad Genetics Management

Management criteria checks 2/4

Myriad Genetics' CEO is Paul Diaz, appointed in Aug 2020, has a tenure of 4.25 years. total yearly compensation is $12.11M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $6.19M. The average tenure of the management team and the board of directors is 2.4 years and 4.8 years respectively.

Key information

Paul Diaz

Chief executive officer

US$12.1m

Total compensation

CEO salary percentage9.0%
CEO tenure4.3yrs
CEO ownership0.4%
Management average tenure2.4yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Nov 02
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Nov 02
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Sep 20
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Aug 30
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking

Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Jul 17
Is Myriad Genetics (NASDAQ:MYGN) Weighed On By Its Debt Load?

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Jan 31

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Dec 18
Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Aug 07
Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Apr 13
Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

CEO Compensation Analysis

How has Paul Diaz's remuneration changed compared to Myriad Genetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$116m

Jun 30 2024n/an/a

-US$155m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$12mUS$1m

-US$263m

Sep 30 2023n/an/a

-US$274m

Jun 30 2023n/an/a

-US$248m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$11mUS$1m

-US$112m

Sep 30 2022n/an/a

-US$77m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$13mUS$1m

-US$27m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$97m

Mar 31 2021n/an/a

-US$148m

Dec 31 2020US$16mUS$383k

-US$224m

Compensation vs Market: Paul's total compensation ($USD12.11M) is above average for companies of similar size in the US market ($USD5.43M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Diaz (62 yo)

4.3yrs

Tenure

US$12,108,359

Compensation

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Diaz
CEO, President & Director4.3yrsUS$12.11m0.44%
$ 6.2m
Samraat Raha
Chief Operating Officerless than a yearUS$5.02mno data
Dale Muzzey
Chief Scientific Officer2.8yrsUS$2.23m0.12%
$ 1.7m
Mark Verratti
Chief Commercial Officer7.3yrsUS$2.88m0.32%
$ 4.5m
Scott Leffler
Chief Financial Officerless than a yearno datano data
Natalie Munk
Principal Accounting Officer2.4yrsno data0.048%
$ 670.1k
Kevin Haas
Chief Technology Officer3.8yrsUS$1.64m0.14%
$ 2.0m
Matthew Scalo
Senior Vice President of Investor Relationsno datano datano data
Jennifer Fox
Chief Legal Officerless than a yearno datano data
Glenn Farrell
Senior VP & Chief Marketing Officer1.9yrsno datano data
Shereen Solaiman
Chief People Officer1.7yrsno data0.0031%
$ 44.3k
Patrick Burke
Executive Vice President of Strategy & Innovation3.5yrsno datano data

2.4yrs

Average Tenure

51yo

Average Age

Experienced Management: MYGN's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Diaz
CEO, President & Director4.3yrsUS$12.11m0.44%
$ 6.2m
Paul Bisaro
Independent Director2.1yrsUS$258.48k0.027%
$ 378.8k
Lee Newcomer
Independent Director5.2yrsUS$447.99k0.073%
$ 1.0m
Daniel Skovronsky
Independent Director4.3yrsUS$433.49k0.077%
$ 1.1m
Colleen Reitan
Independent Director5.2yrsUS$443.49k0.029%
$ 415.7k
Heinrich Dreismann
Independent Director14.4yrsUS$443.49k0.12%
$ 1.6m
S. Phanstiel
Independent Chair of the Board15.2yrsUS$563.49k0.16%
$ 2.2m
Rashmi Kumar
Independent Director4.2yrsUS$433.49k0.068%
$ 955.6k

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: MYGN's board of directors are considered experienced (4.8 years average tenure).